News | Visikol

Visikol Joins CELLINK

Griffin Ferrara2021-05-21T08:39:40-05:00Tags: CELLINK, Visikol|

May 20th, 2021 - Today Visikol joins the CELLINK family through acquisition. The acquisition provides CELLINK the opportunity to [...]

Mike Johnson2021-05-02T06:17:06-05:00Tags: NIH|

Over the last five years, Visikol has developed an extensive portfolio of advanced imaging, digital pathology and cell culture [...]

Visikol has been a leader in advanced bioimaging through its portfolio of cutting-edge technologies and innovative drug discovery, bioimaging, [...]

Griffin Ferrara2021-01-18T10:32:43-05:00Tags: expansion, hampton|

2020 was a challenging year for all industries and the life sciences field was no exception. Throughout 2020, Visikol [...]

Tuberculosis (TB) is still one of the top ten leading causes of death globally. Although TB is both preventable [...]

The Visikol research team has developed a novel tissue multiplexing approach which leverages a proprietary antibody [...]

Mike Johnson2020-11-05T10:48:01-05:00

Visikol, a leading drug discovery company focused on advanced imaging, digital pathology and 3D cell culture assays, announced today [...]

Mike Johnson2020-10-05T19:58:39-05:00Tags: H&E, histology, IHC, spheroid|

3D cell culture models (e.g. organoids, spheroids, micro-tissues) provide researchers with the ability to better mimic the in vivo [...]

Mike Johnson2020-09-28T14:55:22-05:00

Visikol is a leading provider of advanced cell culture assays and has recently been expanding its portfolio of in [...]

Mike Johnson2020-03-19T09:38:05-05:00

Today, it is undeniable that we as a society are going through an absolutely unprecedented time in human history [...]